Precipio Announces Q1-2026 Shareholder Update Call
Rhea-AI Summary
Precipio (NASDAQ: PRPO) will host a Q1-2026 shareholder update call on May 18, 2026 at 5:00 PM ET. The call will cover the company’s core businesses and include a first-time moderated live Q&A for investors.
Participants must identify themselves to enter the Q&A; advance questions may be emailed to investors@precipiodx.com. Dial-in: 646.307.1865. A replay will be available about 24 hours after the call on the Investors page.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
PRPO is up 8.99% while key peers show mixed moves: NOTV (-3.7%), PRPH (-5.91%), ADVB (7.45%), BIAF (-0.5%), ISPC (-1.85%). Momentum scanners only flag BDSX down ~4%, indicating today’s move appears stock-specific rather than a broad sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 12 | Shareholder call notice | Neutral | -6.7% | Announced Q4 and year-end 2025 shareholder update call with dial-in details. |
| Mar 10 | Clinical study update | Positive | +3.3% | Joint study with MSK validating Bloodhound BCR::ABL1 assay performance and sensitivity. |
| Feb 25 | Preliminary 2025 results | Positive | -3.9% | Reported 2025 revenues of $24.0M with 30% YoY growth and positive EBITDA. |
| Jan 15 | Balance sheet cleanup | Positive | +0.0% | Repaid $1.1M advance, reduced long-term debt, and cleared 2023 financing warrants. |
| Dec 05 | Conference presentation | Positive | -2.4% | Planned ASH presentation of BCR::ABL1 assay data from 895 patient samples. |
Recent history shows frequent negative or flat reactions to generally positive corporate developments, with only one clearly positive move following favorable news.
Over the last six months, Precipio has reported multiple operational and financial milestones. On Dec 5, 2025 it highlighted BCR::ABL1 assay data at ASH, and on Jan 15, 2026 it detailed major balance-sheet cleanup. Preliminary 2025 revenue growth to $24.0M and strong Q4 metrics were shared on Feb 25 and in the Mar 30 10-K. A joint Bloodhound assay study with Memorial Sloan-Kettering was announced on Mar 10. Prior shareholder calls, like the Apr 2 Q4 update, often saw muted or negative price reactions.
Market Pulse Summary
This announcement schedules a Q1-2026 shareholder update call on May 18, 2026 at 5:00 PM ET, with a moderated live Q&A for the first time. It continues a pattern of frequent shareholder communications following 2025 revenue growth to $24.0M and recent balance-sheet improvements. Investors may focus on management’s commentary around core businesses, liquidity and growth initiatives, alongside disclosures in the latest 10-K noting an operating loss of $1.2 million and going-concern risk.
AI-generated analysis. Not financial advice.
Conference Call will be held on May 18th, 2026, at 5:00 PM EST
NEW HAVEN, Conn., May 06, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q1-2026 shareholder update call on May 18th, 2026, at 5:00 PM ET. The call will include remarks on the company’s current core businesses, as well as a moderated live Q&A session at the end of the Company remarks.
As part of Precipio’s ongoing commitment to transparency and shareholder engagement, this call will be the first time the Company will incorporate a dedicated moderated live Q&A session into its quarterly update call. Management looks forward to addressing investor questions and providing additional insight into the Company’s performance, strategy, and growth initiatives.
Following Ilan Danieli’s remarks, the conference call moderator will invite listeners to log into the Q&A system, where they will need to identify themselves and the organization they represent (or individual investor). Participants who wish to ask a question during the live call should follow the operator’s instructions.
Listeners interested in submitting questions in advance can email their questions to investors@precipiodx.com, and management will do its best to address those questions during the call.
The conference call may be accessed by calling 646.307.1865. All callers should ask for the Precipio Inc. conference call.
A replay of the call will be available approximately 24 hours after the call and may be accessed via the Investors page on Precipio's website, https://www.precipiodx.com/investors/.
About Precipio
Precipio is a healthcare biotechnology company focused on cancer diagnostics. Our mission is to address the pervasive problem of cancer misdiagnoses by developing solutions in the form of diagnostic products and services. Our products and services deliver higher accuracy, improved laboratory workflow, and ultimately better patient outcomes, which reduce healthcare expenses. Precipio develops innovative technologies in our laboratory where we design, test, validate, and use these products clinically, improving diagnostic outcomes. Precipio then commercializes these technologies as proprietary products that serve the global laboratory community and further scales Precipio’s reach to eradicate misdiagnosis.
Availability of Other Information About Precipio
For more information, please visit the Precipio website at https://www.precipiodx.com/ or follow Precipio on X (formerly Twitter) (@PrecipioDx) and LinkedIn (Precipio) and on Facebook. Investors and others should note that we communicate with our investors and the public using our company website (https://www.precipiodx.com), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the targets set herein and related timing. Except for historical information, statements about future volumes, sales, growth, costs, cost savings, margins, earnings, earnings per share, diluted earnings per share, cash flows, adjusted EBITDA, plans, objectives, expectations, growth or profitability and our potential to reach financial independence are forward-looking statements based on management’s estimates, beliefs, assumptions and projections. Words such as “could,” “may,” “expects,” “anticipates,” “will,” “targets,” “goals,” “projects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “predicts,” and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance, are intended to identify such forward-looking statements. These forward-looking statements are only predictions based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and our other reports filed with the U.S. Securities and Exchange Commission. Any such forward-looking statements represent management’s estimates as of the date of this press release only. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Inquiries: investors@precipiodx.com +1-203-787-7888 Ext. 523